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Abstract
SURFACTANT ENHANCED DELIVERY OF C/EBP HOMOLOGOUS PROTEIN AND ANGIOPOIETIN 2
SILENCING RNA TO PREVENT BRONCHOPULMONARY DYSPLASIA IN MOUSE LUNG. John G. Ramirez,
Mansoor A. Syed, Vineet Bhandari. Section of Neonatal-Perinatal Medicine, Department of Pediatrics,
Yale University, School of Medicine, New Haven, CT.
Objective. To determine if poractant alfa (Curosurf®) could serve as a viable vehicle for silencing RNA
(siRNA) delivery. Specifically, we hypothesize that use of Curosurf® as an enhanced delivery vehicle for
C/EBP homologous protein (CHOP) and Angiopoietin 2 (Ang2) siRNA would augment gene silencing,
preventing cell death and bronchopulmonary dysplasia (BPD) in the mouse lung.
Design. Transfection efficiency of Curosurf® was compared to naked siRNA and Lipofectamine 2000®.
MLE-12 cells were transfected with CHOP and Ang2 siRNA using Curosurf®, then exposed to hyperoxic
conditions. Cultures were evaluated for respective protein expression and markers of cell death.
Curosurf® enhanced siRNA therapy was tested in a hyperoxia-induced mouse model of BPD. Protein
expression and lung morphology were assessed and compared to naked siRNA.
Results. Curosurf® significantly improved cell transfection rates when compared to naked siRNA
alone. Cell cultures treated with Curosurf® enhanced CHOP and Ang2 siRNA delivery had significantly
lower levels of expression of their respective protein products. Cleaved caspase 3, a marker of cell
death, was also decreased in cells transfected using Curosurf®. Curosurf® enhanced delivery of Ang2
siRNA had a modest, but significant, improvement in mouse lung morphology in a hyperoxia-induced
model of BPD.
Conclusions.

Curosurf® enhances silencing RNA delivery of C/EBP homologous protein and

Angiopoietin 2, resulting in an improvement in mouse lung phenotype in a hyperoxia-induced model
of BPD.
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Introduction
Background
Prior to the introduction of the mechanical ventilator to the neonatal intensive care unit
in the 1960s, premature infants with respiratory distress syndrome (RDS) either died
within the first week of life or survived with respiratory sequelae. In 1967 Northway et al
described a new syndrome that affected premature infants with RDS who received
prolonged treatment of high concentrations of supplemental oxygen via mechanical
ventilation with high peak inspiratory pressures.1 The surviving infants of this cohort had
a mean gestational age of 34 weeks and a mean birth weight of 2.3kg. This form of chronic
lung disease was characterized by an oxygen requirement at 28 days of life and
progressive radiographic changes.
The syndrome was coined as bronchopulmonary dysplasia (BPD) in order to emphasize
the fact that the disease process effected all tissues of the lung. Hyperinflation and
atelectasis, along with a cystic and scarred lung appearance were characteristic findings
on chest x-ray. Pathologic examination was characterized by smooth muscle hypertrophy,
inflammatory infiltrates, interstitial fibrosis, and emphysema. These patients frequently
remained oxygen and ventilator dependent beyond the initial few weeks of life and
developed chronic lung changes and abnormal pulmonary function. Infants with severe
lung damage had a high mortality secondary to progressive respiratory failure, usually
within the first weeks of life.
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To study the long-term sequelae Northway et al conducted a follow up study of their
original cohort.2 Most of these adolescents and young adults had some degree of
pulmonary dysfunction characterized by airway obstruction, airway hyperreactivity, and
hyperinflation. Approximately a quarter of the patients in this cohort had severe
pulmonary dysfunction, including persistent symptoms of respiratory difficulty.
The “New” BPD
Preterm delivery affects 12.5% of pregnancies in the United States. These premature
infants are at a higher risk for complications and unique medical problems. BPD is the
most common chronic lung disease of infancy; it persists even with advancements having
been made in the medical management of premature infants. During the era of “classical”
or “old” BPD, few patients survived with birth weights less than 1 kg and a gestational age
less than 28 weeks.3 An increasing number of patients born at a younger gestational age
are now surviving past infancy. Despite advancements in premature neonatal care the
incidence of BPD in all preterm birth survivors has not decreased over time.4 However,
the demographics of the patient population has changed owing to the increased survival
of the highly premature infants, specifically very low birth weight (<1500 g) and extremely
low birth weight infants (<1000 g), and those <30 weeks’ gestation.5
The “new” BPD, henceforth referred to simply as BPD, is a milder form of lung disease
compared to “classic” BPD. The diagnosis and severity of BPD are defined by specific
diagnostic criteria.6 A clinical diagnosis of BPD for infants <32 weeks gestational age
requires that the patient have a supplemental oxygen requirement at 28 days of life. The
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severity of disease is defined by the supplemental oxygen need and/or respiratory
support at 36 weeks corrected gestational age, or at the time of discharge. This can range
from needing no supplemental oxygen to requiring positive pressure support.
The pathology of BPD is characterized by an impairment of alveolar development,
resulting in alveolar hypoplasia.7 Pathologic examination of infants who died with BPD
reveals lungs with fewer number of alveoli and increased alveolar diameters.8
Inflammation is generally milder with less fibrosis and absence of smooth muscle
hypertrophy when compared to “old” BPD. Notably, the pulmonary microvasculature is
also disrupted and features an abnormal vessel network with dysregulated vessel
proliferation, dysmorphic vessels, and thickened alveolar septa.9
The possible sequelae of BPD is still under investigation, however, the available data
would appear to suggest significant long-term morbidity. Studies show that BPD survivors
are likely to suffer from persistent respiratory symptoms requiring medication, although
no correlation was found between gestational age or duration of ventilatory support.10
Investigations of lung function in this population have revealed the development of
substantial airway obstruction, as well as persistence of impaired alveolar
development.3,10 These children were also more likely to suffer from chest deformities
and asthma. Recent research has also identified pulmonary artery hypertension as a
sequela of BPD, with one study finding a median age of 4.8 months at the time of
diagnosis.11

8

In order to discuss the proposed therapeutic intervention explored in this paper, it is
important to review pertinent fetal lung development. Gaining insight into human lung
development will assist in understanding the etiology of BPD and potential avenues for
intervention.
Fetal Lung Development
Human lung development is a complex and highly regulated process involving the
coordination between surface epithelium, supporting interstitial tissue, blood vessels,
and numerous regulatory factors.12,13 During the first half of fetal life (embryonic phase)
the major airways of the lung develop from the foregut. By 16 weeks’ gestation
(pseudoglandular phase), blood vessels that supply the lung and the major conducting
airways have formed. Through 25 weeks’ gestation (canalicular phase) the airways widen
and lengthen, which is followed by the formation of saccules at the terminal bronchioles
(saccular phase). The alveolar-capillary barrier undergoes reorganization, bringing the
epithelial layer in close approximation with the capillary endothelium. By 35 weeks’
gestation (alveolar phase) the lung is in its final phase of development – alveolarization
of the distal lung saccules. The result is a 4-fold increase in lung volume from 29 weeks’
gestation to term and a concomitant increase in available surface area for gas exchange.
This maturation also coincides with a reduction of interstitial tissue, which serves to
facilitate effective diffusion of gases. Lung development continues in the months and
years following birth with continued alveolarization and remodeling of the interalveolar
septa.14
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During the late canalicular/early saccular phase (25-35 weeks’ gestation) the cuboidal
epithelium is replaced by simple squamous epithelium. Ninety-five percent of the alveolar
surface is composed of Type I epithelial cells with Type II epithelial cells making up the
remainder (although Type II pneumocytes dominate in numbers overall – 60%).15 Type II
pneumocytes serve as progenitor cells; they retain the capacity to divide and differentiate
when Type I cells become damaged.16 Type II epithelial cells are also responsible for
producing and elaborating surfactant, a lipoprotein complex that lowers surface tension
at the air-water interface, thereby preventing alveolar collapse during expiration.
Lamellar bodies appear within Type II cells at 24 weeks’ gestation, concomitant with the
initiation of surfactant production, and are responsible for storing the lipoprotein
complex. However, adequate amounts of surfactant are not produced until 35 weeks’
gestation.17 Type I epithelial cells are specialized to facilitate the diffusion of gases across
the alveolar-capillary barrier. Organelles within these cells are clustered around the
nucleus, resulting in a highly attenuated endothelial lining. Pinocytotic vesicles can be
found within the cytoplasm of this thin portion, which are thought to play an important
role in the turnover of surfactant.18 However, surfactant reuptake is thought to be chiefly
mediated by Type II cells via surfactant protein (SP) mediated endocytosis.19-22
Pathogenesis of BPD
Early investigations into the etiology of the “old” BPD hypothesized that the
pathophysiology was due to oxygen toxicity and baro/volutrauma from mechanical
ventilation.23,24 Later studies in newborn mice demonstrated that exposure to oxygen
alone could account for many of the changes seen in patients with BPD.25,26 When these
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mice were exposed to continuous atmospheric conditions of hyperoxia they developed
an impairment of lung development, specifically a decrease in alveolarization and mild
inflammatory response. It is postulated that hyperoxic acute lung injury (HALI) is
mediated by reactive oxygen species, both from high oxygen ventilation and
inflammatory cells, which activate extrinsic and mitochondrial cell death pathways,
resulting in cell death with features of necrosis.27
BPD is a disease that effects newborn infants and involves the impairment of normal lung
growth and development. The hallmark of the disease is impaired alveolarization. As
stated above, premature infants comprise the patient population of BPD as it exists today.
These premature infants are born with underdeveloped lung anatomy that is deficient in
proper alveolar numbers and biochemical activity. The architecture of the lung is
unoptimized for efficient gas exchange at the alveolar-capillary barrier, while surfactant
production is inadequate to prevent alveolar collapse. As mentioned previously, lung
development is a complex and highly coordinated process – thus BPD is likely the result
of interference with the formation of terminal respiratory airways, alveoli, and
microvasculature that supplies these areas.12
The etiology of BPD as we know it today is multifaceted, with multiple major inciting
factors acting synergistically to develop the disease state. Preterm neonates are more
susceptible to developing chronic lung disease as they are born with a surfactant
deficiency secondary to immature Type II alveolar cells. The use of invasive, prolonged
mechanical ventilation causes direct damage to the nascent alveoli which have limited
repair capacity. Because the pulmonary antioxidant system develops alongside the
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surfactant system, high levels of supplemental oxygen can cause significant oxidative
stress injury.17 Additionally, perinatal sepsis (specifically chorioamnionitis) has been
shown to be a risk factor for BPD after premature birth.28
The common thread among these stressors is injury to the developing alveolar epithelium
with subsequent release of proinflammatory cytokines, chemotactic factors, and an
increase in microvascular permeability. The result is initiation of an inflammatory
response, a process that is known to interfere with formation of the microvasculature and
alveolarization in the developing lung.29,30 An imbalance of inflammatory mediators
causes the activation of cell death pathways followed by resolution and repair. It is this
process which disrupts normal lung architecture and results in the characteristic features
of impaired alveolarization and dysregulated angiogenesis.6
Various biomarkers are associated with BPD including regulatory factors, angiogenic
factors, inflammatory mediators, and markers of oxidative injury.31 Although not yet
routinely used in clinical practice, these biomarkers offer potential avenues of
intervention if they are indeed found to be in a causal relationship with BPD. Therefore
they are of particular research interest. For the purposes of this paper we will focus on
C/EBP homologous protein (CHOP) and Angiopoietin 2 (Ang2), two biomarkers thought
to be involved in the cascade of events leading to dysregulated alveolar development.
Importance of CHOP and Ang2
In addition to the aforementioned extrinsic and mitochondrial cell death pathways, a
third pathway exists which involves the endoplasmic reticulum (ER). Known as the ER
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stress-dependent pathway, this pathway reacts to accumulated unfolded proteins within
the ER by facilitating either improvement in protein folding and processing or inducing
apoptosis.32 This unfolded protein response (UPR) is dependent on the nature of the
inciting stressor. Moreover, the UPR appears to upregulate the expression of genes that
are protective against oxidative injury.33 This implies that reactive oxygen species play a
significant role in the ER stress-dependent cell death pathway. CHOP acts as an important
late-phase mediator in this pathway, with increased levels of CHOP protein favoring cell
death.32
Angiogenesis plays a fundamental role in embryonic and postnatal organ development.
Vascular formation is regulated by growth factors and cytokines, including a family of
vascular growth factors called angiopoietins. Angiopoietins are ligands of the tyrosine
receptor kinase receptor with immunoglobulin and epidermal growth factor homology
domain 2 (Tie2) located on endothelial cells.34 Through this interaction they modulate the
remodeling of blood vessels. Furthermore, angiopoietins can also induce the formation
of new blood vessels when working in concert with vascular endothelial growth factor
(VEGF).
Angiopoietin 1 (Ang1) is a Tie2 receptor agonist. It enhances angiogenesis, induces
vascular maturation, and stabilizes blood vessels thereby decreasing vascular leak. Ang2,
on the other hand, is a Tie2 receptor antagonist. It destabilizes blood vessels, induces
vascular regression, and induces endothelial cell apoptosis.27 Hence spatial and temporal
regulation of Ang1 and Ang2 expression plays a key role in pulmonary vascular network
development.35 Indeed, tracheal aspirates from very preterm infants who go on to

13

develop BPD have been found to contain relatively high levels of Ang2, suggesting an
association with abnormal fetal pulmonary angiogenesis.9,36 Furthermore, hyperoxia has
been shown to be a potent inducer of Ang2 mRNA and protein with resultant HALI
(oxidative injury, inflammation, and cell death) and epithelial necrosis.27
Advancements in Treatment
Neonatal care has changed over the last decade following the recognition of the special
needs of premature infants. Disease prevention starts during the antenatal course as the
potential for developing BPD begins in utero. Tocolytics and antenatal corticosteroids can
protect against respiratory distress by delaying delivery and allowing for lung maturation
to occur.17,37 Surfactant replacement therapy has also played a pivotal role in increasing
patient survival by bridging the gap between birth and adequate endogenous surfactant
production.38 Exogenous surfactant therapy and gentle ventilation techniques have
served to reduce the incidence of stretch injury. The use of lower oxygen concentrations
for resuscitation, as well as administration of antioxidants such as vitamin A, has been
shown to reduce oxidative stress in the newborn.5,39 Aggressive treatment and prevention
of infection is also important, as perinatal infection has been associated with an increased
risk of developing BPD.40 Postnatal corticosteroids have been shown to improve
outcomes in some studies, presumably by stimulating surfactant production, enhancing
antioxidant enzyme synthesis, and suppressing the inflammatory response to injury.41
The common theme in treatment is the prevention of inflammation, thus protecting from
cellular death and promoting normal lung development.5 In keeping with this theme, one
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option that has been explored is the use of short interfering RNA, also known as silencing
RNA (siRNA), to inhibit cell death pathways. Antisense agents, such as siRNA, are used by
eukaryotic organisms to regulate gene expression via the prevention of translation. The
cornerstone of this regulatory pathway involves the conjugation of a strand of siRNA to
proteins of the Argonaute family, thereby forming an RNA-induced silencing complex
(RISC).42 RISCs are effector complexes that are responsible for silencing complementary
single stranded RNA sequences through activation of ribonuclease (RNase).43
Recent studies have demonstrated that administration of CHOP and Ang2 siRNA have
beneficial effects in cell and animal models. CHOP siRNA has been shown to prevent cell
death in alveolar epithelial cells and hyperoxia-induced murine models of BPD.44
Additionally, in vivo BPD models treated with CHOP siRNA benefited by preserved
alveolarization.44 Bhandari et al demonstrated that administration of Ang2 siRNA in vivo
reduced hyperoxia-induced inflammation and cell death.45 Both these studies were
carried out with the use of a transfection reagent in vitro and naked siRNA alone in vivo.
The numerous phosphate groups in RNA are charged at physiologic pH, giving the
molecule an overall negative charge. This would make entry of siRNA into cells difficult as
ionic substances generally cannot cross the lipophilic plasma membrane. Thus,
transfection reagents are commonly used in cell cultures as internalization of naked
oligonucleotides is usually inefficient.43 Typical transfection reagents are lipid-derived,
cationic substances capable of forming liposomes that are specifically designed to deliver
exogenic nucleic acids into eukaryotic cells.43 However, these products are only used in
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cell culture experiments. They are not cleared for use in the clinical setting and can have
considerable cytotoxic effects.46
Surfactants are lipoprotein substances that readily form liposomes in aqueous
solution.47,48 Curosurf® (Cornerstone Therapeutics Inc, Cary, NC) is an extract of natural
porcine lung surfactant consisting of 99% polar lipids and 1% hydrophobic low molecular
weight proteins including SP-B and SP-C, but not SP-A.49 It is routinely used in the
treatment of RDS in premature infants.38,50 Of the commercially available therapeutic
surfactants, Curosurf® has physiologic phosphatidylcholine composition most similar to
that of human surfactant.49 Furthermore, the ultrastructural composition of Curosurf®
consists of roughly 80% lamellar/vesicular structures.49
Given the capacity of surfactants like Curosurf® to form liposomes, the potential for
uptake by alveolar epithelial cells (surfactant turnover), and the obvious therapeutic
benefits for very premature infants, we postulate that Curosurf® could serve as a viable
vehicle for siRNA delivery. Specifically, we hypothesize that use of Curosurf® as an
enhanced delivery vehicle for CHOP/Ang2 siRNA would augment gene silencing,
preventing cell death and BPD in the mouse lung. Our goals in this project were to deliver
CHOP/Ang2 siRNA using Curosurf® as the delivery vehicle in in vitro and in vivo systems
to evaluate the impact on CHOP/Ang2 gene silencing, cleaved caspase 3 protein
expression, and lung morphology in a hyperoxia-induced BPD mouse model.
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Materials and Methods
Cell Culture Work
Cells.

Mouse transformed lung epithelial cells (MLE-12) (American Type Culture

Collection, Manassas, VA) were cultured in DMEM supplemented with 2% fetal bovine
serum (FBS) and 1% penicillin/streptomycin. Cells were cultured in a humidified incubator
under normal growth conditions of 5% CO2 at 37°C. All cell culture work was carried out
by the author.
Transfection fluorescence. One microliter of 20 μM labeled, scrambled siRNA (Thermo
Fisher Scientific, Waltham, MA) was diluted in 500 μL of DMEM. Transfection reagent –
20 μL of Lipofectamine 2000® (Life Technologies, Carlsbad, CA) or 5/10/20 μL of Curosurf®
(Cornerstone Therapeutics Inc, Cary, NC) – was diluted in a separate 500 μL of DMEM.
After 5 min, both solutions were combined, briefly vortexed, and allowed to sit for 15 min
at room temperature to permit transfection complexes to form. MLE-12 cells (2.5 × 105)
were seeded per well in 24-well plates, in 500 μL DMEM enriched with 2% FBS. Three
hundred microliters of transfection complex solution was then added drop-wise to
cultures with gentle swirling to ensure uniform distribution. Cells were then incubated
under normal growth conditions for 24 hours. Cells were then stained with DAPI (Thermo
Fisher Scientific, Waltham, MA) and visualized using an Olympus IX70 fluorescence
microscope with the appropriate fluorescence filters. Photomicroscopy was performed
using cellSens imaging software (Olympus Corp), with a minimum of 3 fields per group.
Cell counts for each image were manually performed.
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siRNA transfection. One microliter of 20 μM siRNA (CHOP or Ang2) (Life Technologies,
Carlsbad, CA) was diluted in 500 μL of DMEM. Transfection reagent – 20 μL of
Lipofectamine 2000® or 10 μL of Curosurf® – was diluted in a separate 500 μL of DMEM.
After 5 min both solutions were combined, briefly vortexed, and allowed to sit for 15 min
at room temperature to permit transfection complexes to form. MLE-12 cells (1 × 106)
were seeded per 60 mm plate in 3000 μL DMEM enriched with 2% FBS. One thousand
microliters of transfection complex solution was then added drop-wise to cultures with
gentle swirling to ensure uniform distribution. Cells were then incubated under normal
growth conditions for 24 hours prior to hyperoxia exposure.
Oxygen exposure. MLE-12 cell cultures were placed in an airtight metallic chamber (30 ×
20 × 20 cm3) containing a plate of autoclaved water to promote proper humidification.
The chamber was flushed with 95% O2 for 5 minutes to purge the room air from the
container. The chamber was then placed in a humidified incubator at 37°C for 16 hours.
Protein isolation and detection. Cell cultures were washed with cold PBS and lysed using
radioimmunoprecipitation assay (RIPA) buffer. Following incubation, lysates were
centrifuged and supernatant containing whole protein was collected. Western analysis
was used to evaluate lysates. Whole protein samples were electrophoresed using 4-20%
polyacrylamide gels and transferred to a polyvinylidene difluoride membrane. CHOP and
Ang2 protein was detected, using β-actin as control. Cleaved caspase 3 was detected as a
surrogate marker for cell death. CHOP antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Ang2 antibody was obtained from R&D Systems
(Minneapolis, MN). β-actin and cleaved caspase 3 antibodies were purchased from Cell
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Signaling Technology (Danvers, MA). Detection of protein-bound antibody was achieved
using enhanced chemiluminescence. Protein levels were evaluated by densitometry using
ImageJ (National Institutes of Health).
Animal Work
Animals. Wild-type (WT) C57BL/6 mice were obtained from Jackson Laboratories (Bar
Harbor, ME). Animals were kept at atmospheric pressure and room temperature, 12-hour
light-dark cycle, and allowed to feed ad lib. Two lactating dams were used, which were
alternated between hyperoxia and room air every 24 hours. A murine model of hyperoxiainduced BPD was used as described in the literature.44,51 Briefly, newborn mice were
exposed to hyperoxia (100% O2) from postnatal day (PN) 1-4, during the saccular stage of
murine lung development. A subgroup of animals were sacrificed on PN5 for lung protein
analysis. Mice were returned to room air and allowed to recover until the BPD phenotype
developed (circa PN14).51 Mice were then sacrificed on PN14 to assess lung morphology.
All animal work was approved by the Institutional Animal Care and Use Committee at the
Yale University School of Medicine (New Haven, CT). The author received help with animal
care, siRNA administration, and oxygen exposure. All other animal work was carried out
by the author.
siRNA administration. Ang2 siRNA (20 μM) was prepared in either RNase-free water or
Curosurf®. One to two drops of these solutions was introduced intranasally into the
pulmonary tree of newborn mice on PN1 and PN3.
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Oxygen exposure. Newborn mice were placed in cages in an airtight Plexiglas chamber
(55 × 40 × 50 cm3) ventilated with 100% O2. Oxygen levels were monitored throughout
via a sensor connected to a relay switch integrated into the oxygen supply circuit.
Hyperoxia exposure was initiated on PN1 and continued through PN4.
Protein isolation and detection. Mice were sacrificed using standard CO2 protocol.
Median sternotomy was performed and right heart perfusion with PBS was done to clear
the pulmonary intravascular space. The lungs were rapidly removed en bloc and frozen in
liquid nitrogen. Tissue samples were added to RIPA buffer solution and homogenized with
an electric homogenizer. Following incubation, lysates were centrifuged and supernatant
containing whole protein was collected. Lung lysates were analyzed for protein content
as described above.
Histology. Lung tissues obtained from newborn mice at PN14 were subjected to a
standard protocol for lung inflation (25 cm) and fixed overnight in 10% buffered formalin.
The fixed tissues were then embedded in paraffin, sectioned (5 μm), and hematoxylin &
eosin stained by the Research Histology Laboratory of the Department of Pathology at
Yale University School of Medicine.
Lung morphometry. Alveolar size was estimated from the mean chord length of the
airspace, as the chord length increases proportionally with alveolar enlargement.52
Images were obtained using an Olympus IX70 fluorescence microscope at 10x
magnification and cellSens imaging software (Olympus Corp). A minimum of 3 fields per
mouse were obtained. Each field was analyzed on a Macintosh computer using a modified
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custom macro in NIH Image (National Institutes of Health).53 Briefly, images were run
through an automated algorithm which processed the images via threshold, smoothing,
and inversion. The processed images were then subjected to logical image match ‘and’
operations with horizontal and vertical grids. At least 200 measurements per field were
made for each animal. The length of the lines overlying air space was averaged as the
mean chord length.
Statistical Analysis
Data are expressed as the mean ± standard error of the mean (SEM). A minimum of 3
samples per group was used. As appropriate, groups were compared with an unpaired
two-tailed Student’s t-test with GraphPad Prism 6.03 (GraphPad Software Inc, San Diego,
CA). In all analyses, P < 0.05 was considered statistically significant.
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Results
Effect of Curosurf® on siRNA transfection in MLE-12 cells
The phenomena of gene silencing expression via RNA interference is dependent on
effective transfection of siRNA. Hence, we first wanted to assess the efficacy of Curosurf®
as a transfection reagent with fluorescent-labeled scrambled siRNA. Lipofectamine 2000®
was used as a positive control as it is known to have very good transfection efficiency.
MLE-12 cells, a pulmonary adenocarcinoma cell line with alveolar ell characteristics, were
selected as a surrogate for alveolar epithelial cells.
As expected, immunofluorescent analysis revealed that detection of scrambled siRNA
within cells was dependent on the use of a transfection reagent (Fig. 1A). Lipofectamine
2000® had a transfection rate of 53%, over a 30-fold increase in efficiency when compared
to siRNA alone (P ≤ 0.0001; Fig. 1B). Among the Curosurf® groups, cells treated with 10
μL had the highest transfection rate at 4.5% (P ≤ 0.0001; Fig. 1B). Cells treated with 20 μL
Curosurf® actually had a slight decrease in transfection efficiency when compared to
siRNA alone (P < 0.05; Fig. 1B). Taken together, these studies show that at proper
concentrations Curosurf® is a modest enhancer of siRNA transfection in alveolar epithelial
cells.
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Figure 1. In vitro effect of Curosurf® on siRNA transfection. (A) Representative fluorescence microscopy
images for (1) untreated, (2) scrambled siRNA, (3) siRNA and Lipofectamine 2000®, (4) siRNA and 5 μL
Curosurf®, (5) siRNA and 10 μL Curosurf®, and (6) siRNA and 20 μL Curosurf®. Red areas indicate presence
of siRNA. (B) Transfection ratios for each group. Each bar represents the mean ± the SEM for a minimum of
3 samples per group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, unpaired t-test. (Curo = Curosurf®,
Lipo = Lipofectamine 2000®)

Curosurf® as a transfection reagent on CHOP expression in MLE-12 cells
Elevated levels of CHOP are associated with cell death via the ER stress-dependent
pathway in the hyperoxia-induced model of BPD.44 Hence, we wanted to evaluate the use
of Curosurf® to augment gene silencing using CHOP siRNA. CHOP protein expression was
assessed by western blot analysis (Fig. 2A). Exposure to hyperoxia resulted in an increase

23

in CHOP when compared to room air. Both Lipofectamine 2000® and Curosurf® treated
groups benefited from a decrease in CHOP protein expression when compared to
untreated hyperoxia and naked siRNA (P ≤ 0.05; Fig. 2B). There was no difference
between the Curosurf® and Lipofectamine 2000® treated groups, suggesting comparable
efficiency in gene silencing. Interestingly, there was no appreciable difference between
hyperoxia and naked siRNA groups. Thus, when used as a transfection reagent, Curosurf®
serves as a potent enhancer of CHOP gene silencing via RNA interference.

Figure 2. In vitro effect of Curosurf® as a transfection reagent on CHOP expression in hyperoxic exposure.
(A) The protein expression of CHOP in MLE-12 cells was ascertained under the conditions described, with
β-actin controls. (B) Corresponding relative CHOP protein expression in MLE-12 cells. Each bar represents
the mean ± the SEM for a minimum of 3 samples per group. *P ≤ 0.05, **P ≤ 0.01, unpaired t-test. (Curo =
Curosurf®, Hyp = hyperoxia, Lipo = Lipofectamine 2000®, siCHOP = CHOP siRNA)
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Figure 3. In vitro effect of Curosurf® as a transfection reagent on Ang2 expression in hyperoxic exposure.
(A) The protein expression of Ang2 in MLE-12 cells was ascertained under the conditions described, with βactin controls. (B) Corresponding relative Ang2 protein expression in MLE-12 cells. Each bar represents the
mean ± the SEM for a minimum of 3 samples per group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, unpaired ttest. (Curo = Curosurf®, Hyp = hyperoxia, Lipo = Lipofectamine 2000®, siAng2 = Ang2 siRNA)

Curosurf® as a transfection reagent on Ang2 expression in MLE-12 cells
Ang2 is an important mediator of epithelial cell death in the hyperoxia-induced model of
BPD.45 Therefore, we wanted to evaluate the potential use of Curosurf® to augment gene
silencing using Ang2 siRNA. Ang2 protein expression was assessed by western blot
analysis (Fig. 3A). Exposure to hyperoxia resulted in an increase in Ang2 when compared
to room air. Both Lipofectamine 2000® and Curosurf® treated groups benefited from a
decrease in Ang2 expression when compare to untreated hyperoxia (P ≤ 0.001 and P ≤
0.01, respectively; Fig. 3B). There was no difference between the Curosurf® and
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Lipofectamine 2000® treated groups, suggesting comparable efficiency in gene silencing.
Interestingly, there was an appreciable difference between hyperoxia and naked siRNA
groups but it did not reach statistical significance. There was a significant decrease in
protein expression when comparing naked siRNA to Lipofectamine 2000® and Curosurf®
(P ≤ 0.05; Fig. 3B). Thus, when used as a transfection reagent, Curosurf® serves as a potent
enhancer of Ang2 gene silencing via RNA interference.
Curosurf® as a transfection reagent on cleaved caspase 3 expression in MLE-12 cells
Studies have shown that hyperoxia exposure causes cellular injury in alveolar epithelial
cells and induces cell death.25-27 Caspase 3 is an executioner protease zymogen that plays
a central role in the activation of cellular death via the intrinsic, extrinsic, and UPR
pathways.32,54 Since cleaved caspase 3 correlates directly with cell death, we wanted to
evaluate the expression of cleaved caspase 3 in cells transfected using Curosurf®.
Cleaved caspase 3 protein expression was assessed by western blot analysis. Cells treated
with CHOP siRNA alone did not experience an appreciable decrease in cleaved caspase 3
expression (Fig. 4A). Qualitatively, Curosurf® appears to enhance attenuation of cleaved
caspase 3 when compared to CHOP siRNA alone (Fig. 4A). Cells treated with Ang2 siRNA
alone did not experience an appreciable reduction in cleaved caspase 3 expression (Fig.
4B). Qualitative analysis suggests that transfection with Curosurf® appears to offer a
considerable reduction of cleaved caspase 3 expression when compared to cells treated
with Ang2 siRNA alone (Fig. 4B). Thus, transfection with CHOP/Ang2 siRNA using

26

Curosurf® appears to enhance attenuation of cleaved caspase 3 expression in alveolar
epithelial cells.

Figure 4. In vitro effect of Curosurf® as a transfection reagent on cleaved caspase 3 expression in hyperoxic
exposure. (A) The protein expression of cleaved caspase 3 in CHOP siRNA transfected MLE-12 cells, with βactin controls. (B) The protein expression of cleaved caspase 3 in Ang2 siRNA transfected MLE-12 cells, with
β-actin controls. (C. Casp 3 = cleaved caspase 3, Curo = Curosurf®, Lipo = Lipofectamine 2000®, siAng2 =
Ang2 siRNA, siCHOP = CHOP siRNA)

Curosurf® as a transfection reagent on Ang2 expression in mice
A murine hyperoxia model of BPD was chosen as previous research has shown that
anatomical and functional changes found in this model mimic those found in human
disease.26,51,55 Ang2 expression was assessed by western blot analysis. Among mice
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treated with Ang2 siRNA, protein expression appears to be attenuated when transfected
with and without Curosurf® (Fig. 5). Qualitative analysis suggests that treatment with
Ang2 siRNA alone appears to offer comparable Ang2 gene silencing when compared to
cells transfected with Curosurf®.

Figure 5. In vivo effect of Curosurf® as a transfection reagent on Ang2 expression in hyperoxic exposure.
The protein expression of Ang2 in C57BL/6 mice was ascertained under the conditions described, with βactin controls. (Curo = Curosurf®, siAng2 = Ang2 siRNA)

Effect of Curosurf® as a transfection reagent on mouse lung morphology
BPD lung morphology is characterized by impaired alveolarization secondary to cellular
injury and inflammation.7 Histologic sections of lung tissue from PN14 mice exposed to
hyperoxia exhibit characteristic enlarged, simplified alveoli (Fig. 6A, Panel 2). The lung
architecture is better preserved in mice treated with Ang2 siRNA with improved
alveolarization (Fig. 6A, Panel 3). Additionally, mice treated with Ang2 siRNA and
Curosurf® seemed to respond with further improvement in alveolarization when
compared to siRNA alone (Fig. 6A, Panel 4).
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Figure 6. Effect of Curosurf® as a delivery vehicle for Ang2 siRNA on pulmonary phenotype. (A)
Representative microscopy images of pulmonary structure in PN14 WT mice exposed to (1) room air, (2)
hyperoxia, (3) hyperoxia treated with siAng2, and (4) hyperoxia treated with siAng2 and Curosurf®. (B)
Mean chord length for each group. Each bar represents the mean ± the SEM for a minimum of 3 samples
per group. *P ≤ 0.05, **P ≤ 0.01, unpaired t-test. (Curo = Curosurf®, Hyp = hyperoxia, PN = postnatal, WT =
wild-type)

The degree of alveolarization can be characterized quantitatively because alveolar size is
directly proportional to chord length.52 Mean chord length of PN14 mice treated with
Ang2 siRNA alone was decreased when compared to the hyperoxia model of BPD;
however, this difference was not statistically significant (P = 0.095; Fig. 6B). Mean chord
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length of mice treated with Ang2 siRNA and Curosurf® was decreased when compared to
both hyperoxia and siRNA alone (P ≤ 0.05; Fig. 6B). Thus, Curosurf® enhances gene
silencing via RNA interference and augments alveolar preservation in vivo.
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Discussion
The use of siRNA therapy in the treatment of BPD offers many advantages and can act in
concert with other treatment modalities. The central premise of siRNA therapy is
interruption of key inflammatory cascade components that lead to impaired
vascularization and alveolarization. RNA interference has the advantage of gene silencing
without altering host DNA. Exogenous nucleic acids introduced into the host are
temporary – they act transiently and are degraded by host RNases. An added benefit of
using RNA interference is the ability to directly targeting the lung when administering
siRNA intranasally. Thus, siRNA therapy is suited for a disease of the premature neonate
as it protects the developing lung until the patient is capable of being weaned from
respiratory support.
Although the use commercially available transfection reagents to enhance transfection in
siRNA therapy is appealing, these reagents are not cleared for clinical use in the United
States. Additionally, studies have shown that these transfection reagents can have
significant cytotoxicity.56,57 Moreover, cationic liposomes cause a release of reactive
oxygen species and induce a marked inflammatory response in pneumocytes.46 This
necessitates the need to explore other transfection enhancing candidates such as
Curosurf®.
Properties of Curosurf®
Curosurf® is unique among the exogenous surfactants currently approved by the FDA for
clinical use in the United States. It is the only natural surfactant extracted from porcine
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lung. Studies have suggested that porcine derived surfactants are most similar in
composition to human surfactant with regards to phosphatidylcholine content.49
However, the relevance of this similarity to clinical practice remains to be investigated.
Furthermore, due to mincing of whole lung in the extraction process, Curosurf® has a
significantly higher proportion of sphingomyelin.49 Orborina et al have shown that
sphingomyelin

is

resistant

to

oxidation,

particularly

when

compared

to

phosphatidylcholines like dipalmitoylphosphatidylcholine (DPPC).58 DPPC is a common
additive in many commercial surfactant preparations; however it is not added to
Curosurf®.49 Thus, in addition to its role as a transfection reagent, Curosurf® itself may
offer direct protection against oxidative damage.
Like the other commercially available surfactants, preparations of Curosurf® lack
surfactant protein SP-A since it is removed in the lipid extraction process.49 SP-A is found
in abundance in natural surfactant and plays an important role in surfactant recycling via
receptor-mediated endocytosis at Type II alveolar cells.19-21 The relatively low transfection
efficiency of Curosurf® in our experiments may be partially attributed to this lack of SP-A.
The use of native SP-A is restricted secondary to limitations imposed by its size and
solubility in isolation and recovery. Animal experiments using surfactant enriched with a
synthetic SP-A analogue have shown superiority in improved lung compliance over
surfactant deficient in SP-A.59 However, the effect on surfactant reuptake was not
investigated. The use of Curosurf® preparations enriched with synthetic SP-A in siRNA
therapy is something that could be investigated in future studies.

32

Hyperoxic injury during the late canalicular/early saccular phase of lung development has
been implicated in the pathogenesis of BPD.27 Hence, we decided to investigate the use
of Curosurf® in RNA interference using two mediators of cell death in BPD: CHOP and
Ang2. These two proteins were chosen because they act upon differing pathways that
ultimately lead to inflammation and hyperoxia-induced cell death.
Curosurf® as a transfection reagent in vitro
Internalization of naked RNA is inefficient in cell cultures because negatively charged
oligonucleotides have to cross the hydrophobic cell membrane. Transfection regents such
as Lipofectamine 2000® can enhance internalization by an order of magnitude or more.
In our study, Lipofectamine 2000® improved transfection by 30 fold, whereas Curosurf®
had a transfection rate of 4.5% – a modest 2.5 fold improvement over naked siRNA (Fig.
1). Despite this, transfection with Curosurf® proved to have a potent effect on gene
silencing (Fig. 2 & Fig. 3). Moreover, Lipofectamine 2000® has the potential for
considerable cytotoxicity.46,56 Curosurf® on the other hand is relatively innocuous –
animal studies and clinical trials have shown that it has a low cytotoxic profile.60-62 Taken
together, this makes Curosurf® an appealing candidate for use in siRNA therapy.
Cleaved caspase 3 expression, a marker of cell death, was also attenuated with Curosurf®
enhanced siRNA therapy in vitro (Fig. 4). Hence, although the transfection efficiency of
Curosurf® is relatively low when compared to Lipofectamine 2000®, it had an appreciable
effect on suppressing cell death. This suggests that RNA interference is sensitive to even
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modest increases in siRNA internalization – small improvements in transfection efficiency
can markedly prevent cell death.
Choo-Wing et al have previously investigated the relationship between CHOP expression
and cell death in alveolar epithelial cells exposed to hyperoxia.44 They found that CHOP
siRNA reduced CHOP protein expression and cell death in MLE-12 cells exposed to 24 h
hyperoxia. Our studies did not show a decrease in CHOP protein expression with naked
siRNA alone. However, we did find that administration of CHOP siRNA with Curosurf®
significantly reduced CHOP protein expression (Fig. 2). This difference is likely due to our
higher seeded cell count, resulting in a higher cell density and relatively low dose of siRNA
in our experiments. Although not measured directly, our work suggests that cell death
would also be ameliorated as levels of cleaved caspase 3 are reduced when Curosurf® is
employed as a transfection reagent (Fig. 4A). Hence, our results suggest that Curosurf®
has a marked effect on enhancing CHOP gene silencing, decreasing cell death.
The use of Ang2 siRNA has not been investigated in MLE-12 cells. Our results suggest that
internalization of Ang2 siRNA is inefficient without the use of a transfection reagent.
Although the protein expression of Ang2 was decreased relative to hyperoxia, it was not
found to be statistically significant (P = 0.26, Fig. 3). However, Curosurf® enhanced the
transfection efficacy of Ang2 siRNA as evidenced by the decrease in protein expression
(Fig. 3). Cleaved caspase 3 was also attenuated with Curosurf®, suggesting a reduction in
cell death (Fig. 4B). Transfection with naked siRNA alone did not reduce cleaved caspase
3 expression. The findings suggest that in vitro transfection of naked siRNA is ineffective,
whereas Curosurf® significantly enhances transfection efficiency.
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Curosurf® as a transfection reagent in vivo
Numerous in vivo studies have shown modest internalization of naked oligonucleotides
without the use of a transfection reagent.63,64 Furthermore, RNA interference therapy
using naked siRNA in animal models of BPD has been reported in the literature.44,45,55 Prior
studies investigating Ang2 siRNA therapy have used young adult mice (4-6 weeks of age)
in their BPD models.45,55 The temporal regulation of various angiopoietins plays a key role
in pulmonary vascular network development.35 Hence, the use of appropriately aged
specimens is crucial when investigating animal models of BPD. To our knowledge, the data
we present herein marks the first time that newborn mice with a hyperoxia-induced
model of BPD were used to evaluate the efficacy of Ang2 siRNA therapy.
As mentioned earlier, Ang2 destabilizes blood vessels, induces vascular regression, and
induces endothelial cell apoptosis.27 Bhandari et al previously investigated the
relationship between Ang2 expression and acute lung injury.45,55 They found that
administration of naked Ang2 siRNA reduced protein expression, BAL cellularity, and
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cell death
in a murine model of hyperoxia-induced BPD.45 Our animal studies also suggest that Ang2
expression is attenuated with Ang2 siRNA therapy. Surprisingly, this reduction is
comparable between naked siRNA and Curosurf® enhanced transfection (Fig. 5).
However, analysis of lung morphology reveals that only mice transfected using Curosurf®
had a further significant preservation of lung architecture compared to naked siRNA alone
(Fig. 6). One explanation for this may be the inherent differences between the in vivo and
in vitro transfection processes. Furthermore, Curosurf® may play a more significant role
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in facilitating effective distribution of siRNA to the alveoli than enhancing siRNA
transfection into Type II pneumocytes.
In sum, our research demonstrates that Curosurf® has a modest effect on the
internalization of CHOP/Ang2 siRNA in transfection experiments. We subsequently
appreciated a significant decrease in CHOP/Ang2 protein expression, cleaved caspase 3
expression, and improved lung alveolarization. A proposed sequence of events
summarizing these results is illustrated below (Fig. 7).

Figure 7. Proposed pathway for the effects of siRNA in vivo and in vitro. Hyperoxia leads to increased
expression of CHOP/Ang2, which is decreased with naked siRNA against those two specific genes. This leads
to decreased cleaved caspase 3, resulting in decreased cell death and improved alveolarization. In the right
panel, use of Curosurf® as a delivery vehicle for CHOP/Ang2 siRNA augments the decreased expression of
their respective gene products. This leads to further decrease in cell death and improves alveolarization.

36

Limitations and Future Work
The animal work presented here is limited due to low numbers of mice in each group
(n≥3). Repeating the studies with larger cohorts should provide enough power to resolve
whether or not there is a significant difference in Ang2 protein expression in mice
transfected with and without Curosurf®. Given the improved lung morphology in mice
treated with Curosurf®, we expect that there should indeed be a difference. Although not
covered in our study due to time constraints, investigation is warranted into the effect of
Curosurf® enhanced delivery of CHOP siRNA in newborn mice – specifically, the effect on
hyperoxia-induced pulmonary damage. Furthermore, future studies expanding on the
concepts presented here should include a Curosurf®-only control in order to assess
whether the beneficial effect of Curosurf® enhanced siRNA therapy is in part due to
Curosurf® itself.
We expect that our protocol for Curosurf® enhanced Ang2 siRNA delivery in vivo could be
generalized for any oligonucleotide sequence. This opens up the possibility of testing
Curosurf® enhanced siRNA delivery of many other causal biomarkers and proteins of
interest. It would also be interesting to compare transfection rates of other commercially
available surfactants to Curosurf®.
There are a number of studies that can add to our understanding of how Curosurf®
enhanced siRNA therapy effects the development of BPD. Bronchoalveolar lavage (BAL)
can be performed prior to lung harvest to assess the degree of inflammation. Neutrophil
counts of the BAL fluid give an indication of the degree of inflammation and is thus
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appropriate in ascertaining if Ang2 siRNA ameliorates inflammation. Additionally, the
effect on angiogenesis of the microvasculature should be investigated. This can be
performed in vivo via the use of antibodies against endothelial markers such as platelet
endothelial cell adhesion molecule (PECAM). Finally, plasticity and degree of dysplasia can
be assessed by measuring the Type II epithelial cell count via flow cytometry. Type II
pneumocytes serve as progenitor cells in the lung and play an essential role during normal
lung development.
Bourbon et al have shown some success with the reuptake of surfactant components
using Curosurf®.22 In their studies, liposomes were prepared by sonication of the
suspension for 30 s∙min-1 over a 15 min period. Future RNA interference studies using
Curosurf® may benefit from the use of sonication to facilitate siRNA-laden liposome
formation. Furthermore, as stated earlier, SP-A is thought to be an important mediator in
receptor-mediated endocytosis at Type II alveolar epithelial cells. Enrichment of
Curosurf® with synthetic SP-A may also yield an improvement in transfection ratio in
future studies.59
Conclusion
In summary, our data shows a modest but significant improvement in mouse lung
morphology when Curosurf® is used to enhance Ang2 siRNA delivery in a hyperoxiainduced model of BPD. Our in vitro work with CHOP also suggests that cell death is better
mitigated with Curosurf® enhanced CHOP siRNA delivery. Possible mechanisms for the
observed improvement includes better alveolar distribution of therapeutic siRNA,
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improved surfactant/oligonucleotide uptake by Type II pneumocytes, and intrinsic
antioxidative protection offered by Curosurf®. Further studies are needed to optimize and
validate the observed positive effect of Curosurf® enhanced siRNA delivery in BPD.
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